SCHEMBL7168952

SCHEMBL7168952

CCOC(=O)c1cnc2c(CC)cc(C#N)cc2c1NCc1cccc(Cl)c1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 6/20 0.70
MAPT P10636 7/20 0.46
ALDH1A1 P00352 6/20 0.46
HPGD P15428 4/20 0.46
LMNA P02545 3/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 6/20 0.45
HSD17B10 Q99714 3/20 0.45
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7171736 0.86 PDE5A (0.65) PDE5AMAPTALDH1A1LMNAGAA
SCHEMBL7164683 0.86 PDE5A (0.75) PDE5AMAPTALDH1A1HPGDLMNA
SCHEMBL7167103 0.85 PDE5A (0.84) PDE5AMAPTKDM4ETP53THRB
SCHEMBL7167673 0.85 PDE5A (0.73) PDE5AMAPTALDH1A1HPGDLMNA
SCHEMBL7164772 0.84 PDE5A (0.58) PDE5AMAPTSMN1; SMN2KDM4ETP53
SCHEMBL7170874 0.84 PDE5A (0.74) PDE5AMAPTALDH1A1HPGDLMNA
SCHEMBL5595774 0.84 PDE5A (0.66) PDE5A
SCHEMBL7164937 0.83 PDE5A (0.78) PDE5AMAPTALDH1A1HPGDLMNA
SCHEMBL7160498 0.83 PDE5A (0.75) PDE5AMAPTALDH1A1HPGDLMNA
SCHEMBL7171734 0.83 PDE5A (0.61) PDE5AMAPTSMN1; SMN2KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase BI YINGZHI (US) 2003-12-04 US claimed
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase BRISTOL-MYERS SQUIBB COMPANY 2002-11-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE3A, PDE2A PDE5A 1/4885MAPT 4486/4885ALDH1A1 301/4885
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE2A, PDE3A PDE5A 1/4885MAPT 4376/4885ALDH1A1 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.